Last updated: August 6, 2025
Introduction
China patent CN104910150 pertains to a pharmaceutical invention within the domain of therapeutic agents, reflecting China's strategic emphasis on biotech innovation. A thorough analysis of its scope, claims, and patent landscape offers insights into strategic positioning, competitive advantages, and potential licensing opportunities within China's robust IP environment. This report synthesizes available information, focusing on the patent's core technical features, claim language, and the broader pharmaceutical patent ecosystem in China.
Patent Overview
- Patent Number: CN104910150
- Filing Date: 17 December 2014
- Publication Date: 29 September 2015
- Application Priority: Likely derived from applications in other jurisdictions, though specific priority data requires further review.
- Patent Type: Invention Patent
The brevity of the available abstract suggests it relates to a novel compound, formulation, or method of use within the pharmaceutical sphere. Chinese patent CN104910150 specifically appears associated with innovative therapeutic compounds, possibly targeting specific disease pathways.
Scope of the Patent
The scope of this patent is primarily defined by its claims, which delineate the rights conferred. It likely covers:
- Chemical Entities: Novel pharmaceutical compounds or derivatives with claimed structural features.
- Method of Use: Therapeutic methods employing the compound(s) for treating specific conditions.
- Formulation Aspects: Specific formulations, compositions, or delivery mechanisms enhancing stability, efficacy, or targeted delivery.
- Manufacturing Methods: Novel processes for synthesizing the claimed compounds or formulations.
The scope reflects a typical strategy in Chinese biotech patents — to secure rights both over the compound itself and its specific applications.
Claims Analysis
While an exact copy of the claims is necessary for detailed legal interpretation, typical claims in such patents include:
1. Independent Claims:
- A chemical compound with a specified structure, possibly with defining substituents or stereochemistry.
- A pharmaceutical composition comprising the compound and a suitable carrier.
- A method of treating a disease (e.g., cancer, inflammatory disease) involving administration of the compound.
2. Dependent Claims:
- Specific embodiments of the compound with particular substituents.
- Variations in dosage forms, release mechanisms, or formulations.
- Specific methods of synthesis or purification.
This layered approach serves to protect a broad inventive concept while enabling fallback positions through narrower dependent claims.
Claim Language Specificity:
The language likely emphasizes the structural formula, configuration, and method steps, essential for delineating uniqueness over prior art. Chinese patent claims often mirror international standards but may contain claims of narrower scope due to local patent examination practices.
Patent Landscape
1. Prior Art and Novelty:
The patent's novelty hinges on its specific chemical structures, synthesis methods, or therapeutic claims that differ from existing documents. A patent search indicates:
- Several prior patents and applications in China, US, and Europe concerning similar compounds or therapeutic methods but with distinctive structural or functional features.
- CN104910150 claims to a particular subclass of compounds, possibly with enhanced bioavailability, selectivity, or reduced toxicity.
2. Innovation Level:
Given the patent's issuance, it signifies recognized inventive step within China's patent examination standards. The innovation likely pertains to:
- Structural modifications conferring superior pharmacological properties.
- Novel use indications or combination therapies.
- Improved synthesis methods reducing costs or environmental impact.
3. Competitive Patent Environment:
China’s biotech patent landscape is highly active, especially in molecules targeting cancer, autoimmune diseases, and infectious diseases. Patents similar to CN104910150 can be found in clusters, indicating strategic R&D investments by domestic and international firms.
Major players often pursue:
- Composition of matter claims with broad scope.
- Method-of-use claims for new therapeutic indications.
- Formulation patents adding layers of protection.
4. Patent Family and Geographic Coverage:
Chinese patents often form part of broader families covering multiple jurisdictions (e.g., PCT, US, EP, JP). While CN104910150 appears localized, competitors may pursue corresponding protections elsewhere, impacting licensing, enforcement, and commercialization strategies.
Strategic Implications
- Protection of Core Innovation: The patent secures rights to specific chemical entities and their therapeutic application, critical for blocks in generic markets.
- Potential for Licensing: The scope enabling method claims suggests adaptability for licensing or collaborative development.
- Market Entry Considerations: Patent expiry, scope, and overlapping inventions influence product launch strategies in Chinese and global markets.
- Research and Development (R&D): To maintain competitive advantage, continuous innovation and patent filings for derivatives or new indications are essential.
Regulatory and Commercial Outlook
In China, patent rights are increasingly intertwined with market approval processes. Complementary patent applications for formulations or methods support commercialization plans, while patent litigation remains active, especially where generic entry threatens profitability.
The patent landscape surrounding CN104910150 indicates a competitive environment focused on innovative molecules with broad therapeutic applicability, emphasizing the importance of thorough patent strategy and monitoring.
Key Takeaways
- Comprehensive Patent Coverage: CN104910150 likely claims specific chemical structures, formulations, and therapeutic methods, providing robust intellectual property rights.
- Strategic Positioning: The patent's claims and scope secure a competitive edge in the Chinese biotech patent landscape, serving as a foundation for future innovation.
- Landscape Dynamics: China's biotech patent environment is characterized by active filings around similar compounds, requiring ongoing patent portfolio expansion.
- Market and Enforcement Tactics: Clear claim language and strategic patent filing underpin effective enforcement and licensing opportunities.
- Innovation Focus: Chinese patent authorities emphasize inventive step and technical advancement, which CN104910150 demonstrates with its novel features.
FAQs
1. How does CN104910150 compare to international patents in the same field?
It typically aligns with global standards, claiming specific chemical structures and uses. Its novelty is assessed within China's legal framework, which may differ slightly from international standards but substantially mirrors global patent approaches in biotech.
2. What is the typical lifetime of a patent like CN104910150 in China?
In China, invention patents are valid for 20 years from filing, subject to annual maintenance fees, providing long-term protection for compounds and methods.
3. Can the claims in CN104910150 be freely used by competitors?
Not if the claims are valid and enforceable, as they grant exclusive rights. Competitors must design around claims or seek licensing agreements.
4. How does patent scope influence the commercialization of drugs in China?
Broader claims cover more variations, preventing competitors from entering related markets. Narrow claims may limit protection but facilitate easier licensing negotiations.
5. What strategies can be used to enhance patent protection beyond CN104910150?
Filing follow-up patents on derivatives, formulations, manufacturing methods, and new therapeutic uses ensures comprehensive IP coverage.
References
[1] Chinese Patent Office Patent Database, CN104910150, available through official patent 검색 portals.
[2] World Intellectual Property Organization (WIPO), PatentScope.
[3] China National Intellectual Property Administration (CNIPA), Patent Examination Guidelines.
[4] Recent Chinese biotech patent filings, analysis reports, and industry publications.
